Upstream Bio, Inc. (UPB)
1.59
-0.41
(-20.50%)
USD |
NASDAQ |
Nov 20, 16:00
1.62
+0.03
(+1.89%)
After-Hours: 20:00
Upstream Bio Total Assets (Quarterly) : 245.99M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 245.99M |
| June 30, 2026 | 281.17M |
| March 31, 2026 | 318.05M |
| December 31, 2025 | 353.77M |
| September 30, 2025 | 391.20M |
| Date | Value |
|---|---|
| June 30, 2025 | 420.52M |
| March 31, 2025 | 456.17M |
| December 31, 2024 | 481.72M |
| September 30, 2024 | 232.70M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.794B |
| Alnylam Pharmaceuticals, Inc. | 7.995B |
| Anika Therapeutics, Inc. | 189.60M |
| Savara, Inc. | 155.93M |
| Arrowhead Pharmaceuticals, Inc. | 1.810B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 12.02M |
| Shareholders Equity (Quarterly) | 233.98M |
| Debt to Equity Ratio | 0.0034 |
| Current Ratio | 20.45 |
| Net Debt Paydown Yield | 0.05% |